Selective serine arginine protein kinase (SRPK) 1 inhibitor (Ki
= 0.89 μ
M). Inhibits SRPK2 at higher concentrations. Does not significantly inhibit other SRPKs such as CLK1 and CLK4, or other classes of SR kinases. Down-regulates expression of VEGF165
but does not affect VEGF165b
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases.
Oltean et al.
SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity.
Gammons et al.
Utilization of host SR protein kinases and RNA-splicing machinery during viral replication.
Fukuhara et al.